Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/170691
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ettcheto Arriola, Miren | - |
dc.contributor.author | Busquets Figueras, Oriol | - |
dc.contributor.author | Sánchez-López, E. (Elena) | - |
dc.contributor.author | Cano Fernández, Amanda | - |
dc.contributor.author | Manzine, Patricia | - |
dc.contributor.author | Verdaguer Cardona, Ester | - |
dc.contributor.author | Olloquequi, Jordi | - |
dc.contributor.author | Auladell i Costa, M. Carme | - |
dc.contributor.author | Folch, Jaume | - |
dc.contributor.author | Camins Espuny, Antoni | - |
dc.date.accessioned | 2020-09-17T11:26:33Z | - |
dc.date.available | 2021-05-26T05:10:24Z | - |
dc.date.issued | 2020-05-26 | - |
dc.identifier.issn | 1746-0441 | - |
dc.identifier.uri | http://hdl.handle.net/2445/170691 | - |
dc.description.abstract | Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor that is approved for the treatment of Parkinson's disease (PD) associated with L-DOPA / L-amino acid decarboxylase inhibitor (DDI) therapy allowing for prolonged activity due to a more continuous supply of L-DOPA in the brain. Thus, OPC decreases fluctuation in L-DOPA plasma levels and favours more constant central dopaminergic receptor stimulation, thus improving PD symptomatology. Areas covered: This review evaluates the preclinical development, pharmacology, pharmacokinetics and safety profile of OPC. Data were extracted from published preclinical and clinical studies published on PUBMED and SCOPUS (Search period: 2000-2019). Clinical and post-marketing data were also evaluated. Expert opinion: OPC is a third generation COMT inhibitor with a novel structure. It has an efficacy and tolerability superior to its predecessors, tolcapone (TOL) and entacapone (ENT). It also provides a safe and simplified drug regimen that allows neurologists to individually adjust the existing daily administration of L-DOPA. OPC is indicated as an adjunctive therapy to L-DOPA/DDI in patients with PD and end-of-dose motor fluctuations who cannot be stabilised on those combinations. Abbreviations: 3-OMD, 3-O-methyldopa; 6-OHDA, 6-hydroxydopamine; BG, basal ganglia; COMT, Catechol-O-methyltransferase; DDI, decarboxylase inhibitors; ENT, Entacapone; FDA, Food and Drug Administration; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; OPC, Opicapone; PD, Parkinson's disease; TOL, Tolcapone; GDNF, Glial cell-line-derived neurotrophic factor; NTN, neurturin; ICV, Intracerebroventricular; PDUFA, Prescription Drug User Fees Act; EMA, European Medicine Administration; AE, Adverse event BG, Basal ganglia. QD, once a day. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1080/17460441.2020.1767580 | - |
dc.relation.ispartof | Expert Opinion on Drug Discovery, 2020, vol. 1, num. 11 | - |
dc.relation.uri | https://doi.org/10.1080/17460441.2020.1767580 | - |
dc.rights | (c) Informa Healthcare, 2020 | - |
dc.source | Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) | - |
dc.subject.classification | Malaltia de Parkinson | - |
dc.subject.classification | Malalties neurodegeneratives | - |
dc.subject.classification | Farmacologia | - |
dc.subject.classification | Utilització de medicaments | - |
dc.subject.other | Parkinson's disease | - |
dc.subject.other | Neurodegenerative Diseases | - |
dc.subject.other | Pharmacology | - |
dc.subject.other | Drug utilization | - |
dc.title | The Preclinical discovery and development of opicapone for the treatment of Parkinson's Disease | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 702145 | - |
dc.date.updated | 2020-09-17T11:26:33Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia) Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
702145.pdf | 535.39 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.